TLDR Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
This study evaluated the efficacy of ritlecitinib, a selective JAK3 and TEC family inhibitor, in treating adolescents with moderate-to-severe alopecia areata (AA). Conducted as a single-center, retrospective observational study, it included 11 patients aged ≥ 12 years, treated with ritlecitinib 50 mg daily for 24 weeks. Results showed that 27.3% of patients achieved near-complete hair regrowth (SALT ≤ 10), and 45.5% showed substantial improvement (SALT ≤ 20) by Week 24. Significant reductions in SALT scores were observed as early as Week 8. Eyebrow and eyelash improvements were also noted, with no serious adverse events reported. These findings align with previous trial data, suggesting ritlecitinib as a promising treatment for adolescent AA, though larger studies are needed to confirm these results.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
